Tislelizumab

Generic Name: Tislelizumab

Brand Names: Tevimbra, Tizveni

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1858168-59-8

Unique Ingredient Identifier: 0KVO411B3N

Background: Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).

Indication: ⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。

⑵用于治疗局部晚期或转移性尿路上皮癌。

⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。

⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。

⑸用于治疗晚期恶性实体瘤

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

Phase 2

Completed

Conditions: Locally Advanced or Metastatic Urothelial Bladder Cancer

Interventions: Drug: Tislelizumab

First Posted Date: 2019-07-01

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 113

Registration Number: NCT04004221

Locations: 🇨🇳
Fudan University Hua Dong Hospital, Shanghai, Shanghai, China
🇨🇳
Xiangya Hospital central South University, Changsha, Hunan, China
🇨🇳
The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China

and more 27 locations

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Phase 3

Recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: Tislelizumab
Drug: Placebo
Drug: Cisplatin
Drug: Gemcitabine Hydrochloride
Drug: Carboplatin

First Posted Date: 2019-05-30

Last Posted Date: 2024-11-27

Lead Sponsor: BeiGene

Target Recruit Count: 420

Registration Number: NCT03967977

Locations: 🇨🇳
The Second Affiliated Hospital of Tianjin Medical University, Tianjin, Tianjin, China
🇨🇳
Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
🇨🇳
Chongqing Cancer Hospital, Chongqing, Chongqing, China

and more 14 locations

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Phase 3

Active, not recruiting

Conditions: Esophageal Squamous Cell Carcinoma (ESCC)

Interventions: Drug: Tislelizumab
Drug: Placebo
Drug: Paclitaxel
Drug: Cisplatin
Radiation: Radiotherapy

First Posted Date: 2019-05-21

Last Posted Date: 2024-11-28

Lead Sponsor: BeiGene

Target Recruit Count: 370

Registration Number: NCT03957590

Locations: 🇨🇳
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Northern Jiangsu people's hospital, Yangzhou, Jiangsu, China

and more 30 locations

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Phase 1

Completed

Conditions: Carcinoma, Hepatocellular
Gastric/Gastroesophageal Junction Cancer

Interventions: Drug: Sitravatinib
Drug: Tislelizumab

First Posted Date: 2019-05-08

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 111

Registration Number: NCT03941873

Locations: 🇨🇳
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China
🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

and more 15 locations

Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

Phase 3

Completed

Conditions: Recurrent or Metastatic Nasopharyngeal Cancer

Interventions: Drug: Placebo
Drug: Tislelizumab
Drug: Gemcitabin
Drug: Cisplatin

First Posted Date: 2019-04-23

Last Posted Date: 2024-07-16

Lead Sponsor: BeiGene

Target Recruit Count: 263

Registration Number: NCT03924986

Locations: 🇨🇳
The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
🇨🇳
Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China

and more 37 locations

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Phase 3

Completed

Conditions: Esophageal Squamous Cell Carcinoma (ESCC)

Interventions: Drug: Cisplatin
Drug: Oxaliplatin
Drug: Fluorouracil (5-FU)
Drug: Capecitabine
Drug: Paclitaxel
Drug: Placebo
Drug: Tislelizumab

First Posted Date: 2018-12-21

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 649

Registration Number: NCT03783442

Locations: 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳
Anhui Medical University - The Second Hospital, Hefei, Anhui, China
🇨🇳
Xiangyang Central Hospital, Xiangyang, Hubei, China

and more 173 locations

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Phase 3

Completed

Conditions: Gastric, or Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Placebo
Drug: Tislelizumab
Drug: Cisplatin
Drug: Oxaliplatin
Drug: Capecitabine
Drug: 5-FU

First Posted Date: 2018-12-17

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 997

Registration Number: NCT03777657

Locations: 🇨🇳
Beijing Chao Yang Hospital, Beijing, Beijing, China
🇫🇷
CHU Besançon - Hôpital Jean Minjoz, Besançon, France
🇫🇷
Hôpital de la Timone, Marseille, France

and more 152 locations

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

Phase 3

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Tislelizumab
Drug: Concurrent chemoradiotherapy (cCRT)
Other: Placebo

First Posted Date: 2018-11-19

Last Posted Date: 2020-07-15

Lead Sponsor: Celgene

Target Recruit Count: 1

Registration Number: NCT03745222

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
🇺🇸
Dayton Physicians, LLC, Kettering, Ohio, United States

and more 160 locations

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2

Interventions: Drug: BGB-A425
Drug: Tislelizumab
Drug: LBL-007

First Posted Date: 2018-11-16

Last Posted Date: 2024-07-09

Lead Sponsor: BeiGene

Target Recruit Count: 358

Registration Number: NCT03744468

Locations: 🇮🇹
Fondazione Irccs Istituto Nazionale Dei Tumori, Milano, Italy
🇫🇷
Centre de Lutte Contre Le Cancer Francois Baclesse, Caen, France
🇮🇹
Istituto Di Candiolo Irccs, Torino, Italy

and more 20 locations

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Sitravatinib
Drug: Tislelizumab

First Posted Date: 2018-09-11

Last Posted Date: 2024-11-04

Lead Sponsor: BeiGene

Target Recruit Count: 216

Registration Number: NCT03666143

Locations: 🇦🇺
Icon Cancer Foundation, South Brisbane, Queensland, Australia
🇦🇺
Austin Health, Heidelberg, Victoria, Australia
🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia

and more 16 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy